MC4R and obesity due to melanocortin 4 receptor deficiency: Setmelanotide, a melanocortin-4 receptor (MC4R) agonist, is FDA-approved for obesity related to BBS and has demonstrated significant improvements in appetite control and weight outcomes in clinical trials [[6], [7], [8]].